Inducing competition for MSCs

In a first for induced pluripotent stem cells, Cynata Therapeutics Ltd. is gearing up to test its iPS cell-derived mesenchymal stem cells in humans, following a favorable pre-IND meeting with FDA.

The cells, already in Phase I testing in the U.K. and Australia, would become the first iPS cell-derived therapeutic in the clinic stateside, and offer an alternative to donor-dependent MSCs produced by conventional methods. ...